Table 1.
Clinical characteristics in patients with ST-elevation myocardial infarction receiving timely, delayed, and late pPCI compared to P-I strategy, Norway 2013–2019
| Timely pPCI (≤120 min) |
Delayed pPCI (121–180 min) |
Late pPCI (>180 min) |
P-I strategy | ||||
|---|---|---|---|---|---|---|---|
|
n = 7238 |
n = 1537 |
n = 1012 |
n = 2338 | ||||
| n | P a | n | P a | n | P a | n | |
| Age (years), mean (SD) | 63.3 (11.9) | 0.01 | 65.7 (12.9) | <0.001 | 65.9 (12.8) | <0.001 | 62.5 (11.1) |
| Male, n (%) | 5762 (77) | 0.56 | 1112 (72) | <0.001 | 727 (72) | <0.001 | 1823 (78) |
| Smoking | |||||||
| Previous smoking, n (%) | 2108 (29) | 0.09 | 444 (29) | 0.09 | 313 (31) | 0.28 | 698 (30) |
| Current smoking, n (%) | 2920 (40) | <0.001 | 607 (39) | 0.001 | 375 (37) | <0.001 | 1055 (45) |
| Obesity (BMI > 30 kg/m2), n (%) | 1980 (27) | 0.22 | 454 (30) | 0.55 | 304 (30) | 0.42 | 670 (29) |
| LDL-cholesterol (mmol/L) (SD) | 3.4 (1.1) | 0.02 | 3.3 (1.1) | 0.0001 | 3.3 (1.2) | 0.05 | 3.4 (1.1) |
| Antihypertensive therapy, n (%) | 2539 (35) | 0.81 | 645 (42) | <0.001 | 469 (46) | <0.001 | 828 (35) |
| Diabetes, n (%) | 886 (12) | 0.24 | 252 (16) | <0.001 | 180 (18) | <0.001 | 265 (11) |
| Previous coronary heart disease | |||||||
| Myocardial infarction, n (%) | 684 (9%) | 0.51 | 174 (11) | 0.16 | 155 (15) | <0.001 | 232 (10) |
| Percutaneous coronary intervention, n (%) | 701 (10) | 0.49 | 180 (12) | 0.13 | 136 (13) | 0.006 | 238 (10) |
| Coronary artery bypass grafting, n (%) | 127 (2) | 0.99 | 38 (2) | 0.12 | 50 (5) | <0.001 | 41 (2) |
| Previous stroke, n (%) | 233 (3) | 0.39 | 74 (5) | 0.002 | 61 (6) | <0.001 | 67 (3) |
| History of heart failure, n (%) | 74 (1) | 0.99 | 35 (2) | 0.002 | 22 (2) | 0.009 | 24 (1) |
| Chronic kidney disease (eGFR < 60 mL/min), n (%) | 932 (13) | 0.21 | 288 (19) | <0.001 | 220 (22) | <0.001 | 271 (14) |
| Medication prior to admittance | |||||||
| Acetylsalicylic acid, n (%) | 1278 (18) | 0.02 | 312 (20) | 0.56 | 265 (26) | <0.001 | 461 (20) |
| Lipid lowering therapy, n (%) | 1512 (21) | 0.66 | 341 (22) | 0.14 | 271 (27) | <0.001 | 476 (20) |
| Beta blocker, n (%) | 1054 (15) | 0.19 | 296 (19) | <0.001 | 240 (24) | <0.001 | 313 (13) |
| ACE/AII receptor inhibitor, n (%) | 1841 (25) | 0.002 | 417 (27) | <0.001 | 298 (29) | <0.001 | 515 (22) |
| Diuretics, n (%) | 830 (11) | <0.001 | 200 (13) | <0.001 | 135 (13) | <0.001 | 202 (9) |
| Anticoagulation therapy, n (%) | 280 (4) | <0.001 | 94 (6) | <0.001 | 91 (9) | <0.001 | 41 (2) |
| Out-of-hospital cardiac arrest, n (%) | 612 (8) | 0.73 | 154 (10) | 0.05 | 52 (5) | 0.002 | 192 (8) |
| Median time delay onset of symptoms to FMC, min (25th–75th percentile) | 54 (26–120) | <0.001 | 74 (30–155) | <0.001 | 90 (33–182) | 0.002 | 96 (60–160) |
| Median time delay from FMC to reperfusion therapy, min (25th–75th percentile) | 82 (65–100) | <0.001 | 140 (130–156) | <0.001 | 252 (206–365) | <0.001 | 48 (32–70) |
| Median time delay from admission PCI-hospital to reperfusion therapy, min (25th–75th percentile) | 20 (13–34) | 27 (16–51) | 47 (19–152) | NA | |||
a
Reference: pharmaco-invasive (P-I) strategy.
FMC, first medical contact; pPCI, primary percutaneous coronary intervention.